首页> 外国专利> PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY AND DYSFUNCTION ASSOCIATED TO METABOLIC SYNDROME

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY AND DYSFUNCTION ASSOCIATED TO METABOLIC SYNDROME

机译:药物组合物治疗代谢综合征所致左心室肥大和功能障碍

摘要

The present invention relates to methods and pharmaceutical compositions for the treatment of left ventricular hypertrophy and dysfunction associated to metabolic syndrome. The inventors showed that IGFBP2 heart expression as well as plasmatic levels were decreased in patients with MetS compared to control patients. In a mouse model of diet-induced MetS, cardiac IGFBP2 expression was also decreased and associated with left ventricular hypertrophy. They demonstrated for the first time that cardiac overexpression of human IGFBP2 by a single AAV9-hIGFBP2 injection restored cardiac IGFBP2 levels in mouse heart and prevented left ventricle wall thickening, hypertrophy and dysfunction.In particular, the present invention relates to a method of treating left ventricular hypertrophy and dysfunction associated to metabolic syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one agent capable of raising the expression of IGFBP2.
机译:本发明涉及用于治疗与代谢综合征相关的左心室肥大和功能障碍的方法和药物组合物。发明人表明,与对照患者相比,MetS患者的IGFBP2心脏表达以及血浆水平降低。在饮食诱导的MetS的小鼠模型中,心脏IGFBP2表达也降低并且与左心室肥大相关。他们首次证明了通过单次AAV9-hIGFBP2注射后人IGFBP2的心脏过表达恢复了小鼠心脏中的心脏IGFBP2水平,并防止了左心室壁增厚,肥大和功能障碍。特别是,本发明涉及一种治疗左需要其的受试者中与代谢综合征相关的心室肥大和功能障碍包括向该受试者施用治疗有效量的至少一种能够提高IGFBP2表达的试剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号